[{"id":"9c9bdd8c-7abe-4b3e-b585-0d05ef9a65f5","acronym":"CodeBreak101","url":"https://clinicaltrials.gov/study/NCT04185883","created_at":"2021-01-18T20:24:19.309Z","updated_at":"2025-02-25T15:11:23.343Z","phase":"Phase 1","brief_title":"Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)","source_id_and_acronym":"NCT04185883 - CodeBreak101","lead_sponsor":"Amgen","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Avastin (bevacizumab) • Mekinist (trametinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Ibrance (palbociclib) • carboplatin • paclitaxel • docetaxel • 5-fluorouracil • everolimus • Vectibix (panitumumab) • Lumakras (sotorasib) • pemetrexed • oxaliplatin • irinotecan • leucovorin calcium • batoprotafib (TNO155) • vociprotafib (RMC-4630) • BI 1701963 • loperamide • zeluvalimab (AMG 404)"],"overall_status":"Recruiting","enrollment":" Enrollment 1200","initiation":"Initiation: 12/17/2019","start_date":" 12/17/2019","primary_txt":" Primary completion: 04/29/2026","primary_completion_date":" 04/29/2026","study_txt":" Completion: 03/13/2028","study_completion_date":" 03/13/2028","last_update_posted":"2025-02-13"},{"id":"67631604-169f-4968-bf77-ff9940ff3dfc","acronym":"","url":"https://clinicaltrials.gov/study/NCT04973163","created_at":"2021-07-22T17:52:57.458Z","updated_at":"2024-07-02T16:35:09.277Z","phase":"Phase 1","brief_title":"A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation","source_id_and_acronym":"NCT04973163","lead_sponsor":"Boehringer Ingelheim","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BI 1823911 • BI 1701963 • midazolam hydrochloride"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/03/2021","start_date":" 08/03/2021","primary_txt":" Primary completion: 11/29/2024","primary_completion_date":" 11/29/2024","study_txt":" Completion: 12/27/2024","study_completion_date":" 12/27/2024","last_update_posted":"2024-04-17"},{"id":"78c12704-ab35-4338-aeed-4cc6fbe8e7c5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04111458","created_at":"2021-01-18T20:06:09.981Z","updated_at":"2024-07-02T16:35:09.407Z","phase":"Phase 1","brief_title":"A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)","source_id_and_acronym":"NCT04111458","lead_sponsor":"Boehringer Ingelheim","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • BI 1701963"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 71","initiation":"Initiation: 10/28/2019","start_date":" 10/28/2019","primary_txt":" Primary completion: 10/31/2024","primary_completion_date":" 10/31/2024","study_txt":" Completion: 10/31/2024","study_completion_date":" 10/31/2024","last_update_posted":"2024-04-16"},{"id":"4bf93b69-0cce-4692-8a52-e1d41b54ad12","acronym":"KRYSTAL 14","url":"https://clinicaltrials.gov/study/NCT04975256","created_at":"2021-07-23T13:52:35.255Z","updated_at":"2024-07-02T16:35:59.402Z","phase":"Phase 1","brief_title":"Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)","source_id_and_acronym":"NCT04975256 - KRYSTAL 14","lead_sponsor":"Mirati Therapeutics Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Krazati (adagrasib) • BI 1701963"],"overall_status":"Completed","enrollment":" Enrollment 7","initiation":"Initiation: 08/12/2021","start_date":" 08/12/2021","primary_txt":" Primary completion: 11/02/2022","primary_completion_date":" 11/02/2022","study_txt":" Completion: 11/15/2022","study_completion_date":" 11/15/2022","last_update_posted":"2022-12-08"}]